283 related articles for article (PubMed ID: 19307946)
21. Germline mutations in the BRCA1 and BRCA2 genes in Turkish breast/ovarian cancer patients.
Manguoglu AE; Lüleci G; Ozçelik T; Colak T; Schayek H; Akaydin M; Friedman E
Hum Mutat; 2003 Apr; 21(4):444-5. PubMed ID: 12655560
[TBL] [Abstract][Full Text] [Related]
22. The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.
Fatouros M; Baltoyiannis G; Roukos DH
Ann Surg Oncol; 2008 Jan; 15(1):21-33. PubMed ID: 17940826
[TBL] [Abstract][Full Text] [Related]
23. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.
Berns EM; Foekens JA; Vossen R; Look MP; Devilee P; Henzen-Logmans SC; van Staveren IL; van Putten WL; Inganäs M; Meijer-van Gelder ME; Cornelisse C; Claassen CJ; Portengen H; Bakker B; Klijn JG
Cancer Res; 2000 Apr; 60(8):2155-62. PubMed ID: 10786679
[TBL] [Abstract][Full Text] [Related]
24. Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Graeser MK; Engel C; Rhiem K; Gadzicki D; Bick U; Kast K; Froster UG; Schlehe B; Bechtold A; Arnold N; Preisler-Adams S; Nestle-Kraemling C; Zaino M; Loeffler M; Kiechle M; Meindl A; Varga D; Schmutzler RK
J Clin Oncol; 2009 Dec; 27(35):5887-92. PubMed ID: 19858402
[TBL] [Abstract][Full Text] [Related]
25. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.
Palacios J; Honrado E; Osorio A; Cazorla A; Sarrió D; Barroso A; Rodríguez S; Cigudosa JC; Diez O; Alonso C; Lerma E; Sánchez L; Rivas C; Benítez J
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3606-14. PubMed ID: 14506147
[TBL] [Abstract][Full Text] [Related]
27. Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?
Evans DG; Howell A
Breast Cancer Res; 2004; 6(1):E7. PubMed ID: 14680492
[TBL] [Abstract][Full Text] [Related]
28. Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online.
De Benedetti VM; Radice P; Pasini B; Stagi L; Pensotti V; Mondini P; Manoukian S; Conti A; Spatti G; Rilke F; Pierotti MA
Hum Mutat; 1998; 12(3):215. PubMed ID: 10660329
[TBL] [Abstract][Full Text] [Related]
29. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
30. Novel BRCA1 and BRCA2 germline mutations and assessment of mutation spectrum and prevalence in Italian breast and/or ovarian cancer families.
Giannini G; Capalbo C; Ristori E; Ricevuto E; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A
Breast Cancer Res Treat; 2006 Nov; 100(1):83-91. PubMed ID: 16847550
[TBL] [Abstract][Full Text] [Related]
31. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
[TBL] [Abstract][Full Text] [Related]
32. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry.
Quenneville LA; Phillips KA; Ozcelik H; Parkes RK; Knight JA; Goodwin PJ; Andrulis IL; O'Malley FP
Cancer; 2002 Nov; 95(10):2068-75. PubMed ID: 12412159
[TBL] [Abstract][Full Text] [Related]
33. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Byrski T; Gronwald J; Huzarski T; Grzybowska E; Budryk M; Stawicka M; Mierzwa T; Szwiec M; Wiśniowski R; Siolek M; Narod SA; Lubinski J;
Breast Cancer Res Treat; 2008 Mar; 108(2):289-96. PubMed ID: 17492376
[TBL] [Abstract][Full Text] [Related]
34. Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.
Arnes JB; Brunet JS; Stefansson I; Bégin LR; Wong N; Chappuis PO; Akslen LA; Foulkes WD
Clin Cancer Res; 2005 Jun; 11(11):4003-11. PubMed ID: 15930334
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of BRCA1 and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations.
Khoo US; Ngan HY; Cheung AN; Chan KY; Lu J; Chan VW; Lau S; Andrulis IL; Ozcelik H
Hum Mutat; 2000 Jul; 16(1):88-9. PubMed ID: 10874312
[TBL] [Abstract][Full Text] [Related]
36. The Brca1 and Brca2 proteins and tumor pathogenesis.
Ingvarsson S
Anticancer Res; 1999; 19(4B):2853-61. PubMed ID: 10652564
[TBL] [Abstract][Full Text] [Related]
37. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
38. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations.
Hudelist G; Wagner T; Rosner M; Fink-Retter A; Gschwantler-Kaulich D; Czerwenka K; Kroiss R; Tea M; Pischinger K; Köstler WJ; Attems J; Mueller R; Blaukopf C; Kubista E; Hengstschläger M; Singer CF
Endocr Relat Cancer; 2007 Dec; 14(4):1053-62. PubMed ID: 18045956
[TBL] [Abstract][Full Text] [Related]
39. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.
Haffty BG; Harrold E; Khan AJ; Pathare P; Smith TE; Turner BC; Glazer PM; Ward B; Carter D; Matloff E; Bale AE; Alvarez-Franco M
Lancet; 2002 Apr; 359(9316):1471-7. PubMed ID: 11988246
[TBL] [Abstract][Full Text] [Related]
40. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma.
Bruchim I; Amichay K; Kidron D; Attias Z; Biron-Shental T; Drucker L; Friedman E; Werner H; Fishman A
Int J Gynecol Cancer; 2010 Oct; 20(7):1148-53. PubMed ID: 21206239
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
